Recall report: Pfizer pulls even more Chantix lots as nitrosamine contamination worries grow
It’s been a month since Pfizer was forced to recall bottles of its anti-smoking drug Chantix, but the counter was set back to zero last week as the company recalled all of its lots of 0.5 mg and 1 mg tablets due to increased levels of nitrosamines.
Distribution of Chantix was stopped in June, and the company recalled four lots of the drug after finding elevated levels of cancer-causing nitrosamines. Then, in July, the FDA said it would still allow certain manufacturers to distribute batches of the drug that have more than the usual nitrosamine levels, so long as it remains under the interim acceptable limit.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.